An interventional study of Exercise and Control in Post-Acute COVID-19 Syndrome, sponsored by University of Nove de Julho. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.
Sponsored by University of Nove de Julho · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil — 9 open to participants now, 10 under way, 2 of them phase 3. Post-Acute COVID-19 Syndrome · Brazil.
Among the 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2024, is one of 12 with no phase, and was the 14th registered.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →9 of the 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil are open now. Recruiting first, the newest first:
Douglas D. Fraser · Sites in Brazil, United States, Canada and 4 more countries
Ages 18–65
University of Nove de Julho · Sites in Brazil
Ages 18+ · Healthy volunteers
University of the State of Santa Catarina · Sites in Brazil
Ages 20–80 · Healthy volunteers
Federal University of São Paulo · Sites in Brazil
Ages 18+
D'Or Institute for Research and Education · Sites in Brazil
Ages 18–65
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 57 across the 18 interventional studies, 72 across the 3 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 21 have an industry lead sponsor. The 10 most frequent:
University of Nove de Julho is the lead sponsor of 246 studies on the registry; 52 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 1 (13%) have results posted.
University of Nove de Julho has 3 studies filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Post-Acute COVID-19 Syndrome with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to assess the effect of a physical exercise program via a mobile application on functional parameters in individuals with post-COVID-19 syndrome. This is a clinical trial involving 60 individuals with post-COVID syndrome who will be randomly assigned to either a control group (physical activity guideline) or an experimental group (app-based training).
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The subjects randomized to this group will perform three app-based training sessions per week for 12 weeks, each session lasting a maximum of 40 minutes.
Behavioral: Exercise
This group will receive a booklet with exercise instructions, and will be recommended the same frequency and duration of exercise as the experimental group
Behavioral: Control
The experimental group will undergo an exercise program using the Recovery App. Participants will receive guidance from researchers about the functionality of the app. The Recovery App includes flexibility, strength, and aerobic training exercises, aiming for a progressive intensity and volume over the weeks.
Also known as: Rehabilitation, Physical activity, Endurance, Resistance exercises
They will receive an exercise booklet based on the Brazilian Physical Activity Recommendations (MINISTRY OF HEALTH, 2021), which recommend 150 minutes of physical activity for adults and seniors.
Change from baseline in 6 min-walk test distance at 12 weeks
The 6-minute walk test performed in a 30-meter corridor, measured in meters
Time frame: Baseline and 12 weeks
Change from baseline in Glittre test at 12 weeks
The test consists in rise from a chair, carry a weighted backpack, walk 10 meters, climb stairs, move objects between shelves (1 kg each), and return. They perform tasks sequentially, transferring items up and down shelves. The route is retraced, ending by sitting back in the initial chair, measured in seconds
Time frame: Baseline and 12 weeks
Change from baseline in sit and stand test at 12 weeks
The test consists in rising from a chair as many times as possible within 30 seconds, measured in number of repetitions
Time frame: Baseline and 12 weeks
Change from baseline in Post-Covid Functional Scale at 12 weeks
The Post-COVID-19 Functional Status Scale assesses limitations following SARS-CoV-2 infection, measured as a score
Time frame: Baseline and 12 weeks
Change from baseline in Patient Functional Scale at 12 weeks
The Patient Functional Scale allows individuals to identify 3 to 5 important activities they consider themselves unable to perform or are having difficulty with due to their condition, measured in a score
Time frame: Baseline and 12 weeks
Change from baseline in Motor Evoked Potential at 12 weeks
The cortical excitability of the quadriceps motor area will be measured using Motor Evoked Potential results in microvolts (µV) using the Transcranial Magnetic Stimulation equipment model MagPro R20 (MagVenture, Denmark) with the parabolic coil model MMC-140-II, measured in kgf
Time frame: Baseline and 12 weeks
Change from baseline in Modified Medical Research Dyspnea Scale at 12 weeks
This scale comprises five items, allowing the patient to select the item that corresponds to how much their dyspnea limits their daily life activities, measured as a score
Time frame: Baseline and 12 weeks
Change from baseline in Chalder Physical Fatigue Scale at 12 weeks
Comprising eight specific statements about physical fatigue to confirm its presence or absence, measured as a score
Time frame: Baseline and 12 weeks
Change from baseline in De Paul Symptom Questionnaire at 12 weeks
The questionnaire evaluate the symptoms of fatigue in different conditions, measured as a score
Time frame: Baseline and 12 weeks
Change from baseline in Quality of Life at 12 weeks
To assess quality of life, the 12-Item Short-Form Health Survey will be used, consisting of twelve items that evaluate eight different dimensions influencing quality of life, measured as a score
Time frame: Baseline and 12 weeks
Change from baseline in Frailty and Sarcopenia at 12 weeks
Frailty will be assessed using the Tilburg Frailty Indicator, while sarcopenia will be evaluated through the Sarcopenia Form questionnaire, both measured as a score
Time frame: Baseline and 12 weeks
Change from baseline in Anxiety and Depressive Symptoms at 12 weeks
Levels of anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale, measured as a score
Time frame: Baseline and 12 weeks
Change from baseline in Pain at 12 weeks
Assessed using the Numeric Pain Rating Scale, measured as a score
Time frame: Baseline and 12 weeks
Change from baseline in Movement Behavior at 12 weeks
Movement behavior will be quantified through a motion sensor, measured in minutes
Time frame: Baseline and 12 weeks
Change from baseline in Barriers to Physical activity at 12 weeks
Specific questionnaire to assess the most prevalent environmental barriers to physical activity, measured as presence or absence
Time frame: Baseline and 12 weeks
Post assessment of Exercise Adherence Assessment Scale
Adherence to exercise interventions will be obtained with the Adherence Assessment Scale
Time frame: 12 weeks
Change from baseline in Blood Pressure at 12 weeks
The clinical resting blood pressure will be assessed using automatic blood pressure monitoring equipment (HEM-7113, OMRON®, Brazil), measured in mmHg
Time frame: Baseline and 12 weeks
Change from baseline in Cardiac Autonomic Modulation at 12 weeks
Cardiac autonomic modulation will be assessed through heart rate variability using a heart rate monitor, measured in RR intervals
Time frame: Baseline and 12 weeks
Change from baseline in Blood Flow and Flow-mediated Dilation at 12 weeks
The measurements of basal blood flow and flow-mediated vasodilation will be obtained through ultrasonography in brachial artery, measured in ml/min or %
Time frame: Baseline and 12 weeks
Change in Spirometry parameters at 12 weeks
Changes in Forced vital capacity, forced expiratory volume in the first second, Peak expiratory flow, forced expiratory flow 25-75% and FEV 1 /FVC ratio
Time frame: Baseline and 12 weeks
System Usability Scale
Scale used to assess the individuals' perception of the app's usability in the group submitted to the intervention
Time frame: 12 weeks
The User Experience Questionnaire
The questionnaire will be applied in experimental group to collect information regarding the user's overall experience with the app, such as: general perception, overall experience, main barriers, and key difficulties in using the app.
Time frame: 12 weeks
Focal group
The focus group will be conducted via video conference with 4 to 10 individuals that participated in experimental group. The guiding questions will aim to understand the user's perception, from usability to effectiveness, including satisfaction and potential improvements to the app.
Time frame: 12 weeks
Plan to share: Yes — The data will be available after the completion of the study and the finalization of the main articles of this projects
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: After the publication of the main articles of the study.
Access criteria: Upon reasonable request
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Jun 2026, 27 months after the start.
Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 27 months is above that.
Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →